Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27649586 | 1.00 | CTSK (0.55) | CTSKHTTCTSLCTSSSIRT5 | |
| SCHEMBL6383945 | 0.89 | CTSK (0.66) | CTSKCTSLCTSSSIRT5CAPN1 | |
| SCHEMBL10035721 | 0.88 | CTSK (0.55) | CTSKCTSLCTSSPSMB8PSMB9 | |
| SCHEMBL10035700 | 0.88 | CTSK (0.55) | CTSKCTSLCTSSPSMB8PSMB9 | |
| SCHEMBL6384215 | 0.87 | CTSL (0.66) | CTSKCTSLCTSSSIRT5CTSB | |
| SCHEMBL27649629 | 0.87 | CTSL (0.66) | CTSKCTSLCTSSSIRT5CTSB | |
| SCHEMBL29372806 | 0.86 | MME (0.61) | CTSKFOLH1CAPN1PSMB8PSMB9 | |
| SCHEMBL31243057 | 0.84 | CTSL (0.57) | CTSKHTTCTSLCTSSSIRT5 | |
| SCHEMBL31243031 | 0.84 | SIRT2 (0.62) | CTSKHTTCTSLCTSSSIRT5 | |
| SCHEMBL9359914 | 0.84 | CTSK (0.60) | CTSKCTSLCTSSCAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492523-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-05 | — | — | EP | disclosed |
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| WO-2003043631-A2 | METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138864-A1 | Method for identifying an enzyme to design anti-cancer compounds | RNASE1, GUSB, DPEP1 | CTSK 333/4885HTT 4648/4885CTSL 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.